Data for: "3D Bioprinting of mature bacterial biofilms for antimicrobial resistance drug testing"



The potential to bioprint and study 3D bacterial biofilm constructs could have great clinical significance at a time when antimicrobial resistance (AMR) is rising to dangerously high levels worldwide. In this study, clinically relevant bacterial species including Escherichia coli, Staphylococcus aureus (MSSA), Methicillin-resistant staphylococcus aureus (MRSA) and Pseudomonas aeruginosa were 3D bioprinted to form mature bacteria biofilms, characterized by Confocal laser scanning microscopy (CLSM) and fluorescent staining. Solid and porous bacteria-laden constructs were reproducibly bioprinted with thicknesses ranging from 0.25 to 4 mm. We demonstrated the 3D bioprinting thicker biofilms (>4mm) than found in currently available in vitro models. Bacterial viability was excellent in the bioprinted constructs, with CLSM observation of bacterial biofilm production and maturation possible for at least 28 days in culture. Importantly, we first time observed the complete five-step biofilm life cycle in vitro, suggesting the formation of mature 3D bioprinted biofilms. Bacterial growth was faster in thinner, more porous constructs whilst constructs crosslinked with BaCl2 concentrations of above 10 mM had superior biofilm formation. 3D MRSA and MSSA biofilm constructs were found to show greater resistance to antimicrobial drugs than corresponding two-dimensional (2D) cultures. Thicker 3D E.coli biofilms had greater resistance to tetracycline than thinner constructs over 7 days of treatment. Our methodology allowed for the precise 3D bioprinting of self-supporting 3D bacterial biofilm structures that developed biofilms during extended culture. 3D biofilm constructs containing bacterial biofilms produce a model with much greater clinical relevance compared to 2D culture models and we have demonstrated their use in antimicrobial testing.
Date made available30 Jul 2019
PublisherUniversity of Strathclyde
Date of data production1 Sept 2017 - 30 Aug 2018

Cite this